Bioxyne Limited (BXN.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 10:00AM AEST
| Previous close | 0.0280 |
| Open | 0.0260 |
| Bid | 0.0240 x 130048500 |
| Ask | 0.0250 x 35000000 |
| Day's range | 0.0260 - 0.0260 |
| 52-week range | 0.0110 - 0.0360 |
| Volume | |
| Avg. volume | 143,291 |
| Market cap | 16.644M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | ∞ |
| EPS (TTM) | N/A |
| Earnings date | 29 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
DENVER, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today that the Company has signed an LOI (letter of intent) with Maya. Together, the two companies plan to co-develop a novel digital therapeutics (DTx) platform. This platform would allow Mydecine to enhance treatment effectiven
© 2022 Yahoo. All rights reserved.
